Merck EBITDA 2006-2018 | MRK

Merck annual and quarterly EBITDA history from 2006 to 2018. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Merck EBITDA for the quarter ending December 31, 2018 was $3.947B, a 23.23% increase year-over-year.
  • Merck EBITDA for the twelve months ending December 31, 2018 was $13.450B, a 17.23% increase year-over-year.
  • Merck 2018 annual EBITDA was $13.45B, a 17.23% increase from 2017.
  • Merck 2017 annual EBITDA was $11.473B, a 4.59% increase from 2016.
  • Merck 2016 annual EBITDA was $10.97B, a 21.2% decline from 2015.
Merck Annual EBITDA
(Millions of US $)
2018 $13,450
2017 $11,473
2016 $10,970
2015 $13,922
2014 $13,374
2013 $14,653
2012 $16,855
2011 $16,403
2010 $10,736
2009 $6,597
2008 $7,716
2007 $7,606
2006 $5,955
2005 $7,567
Merck Quarterly EBITDA
(Millions of US $)
Q4 2018 $3,947
Q3 2018 $3,725
Q2 2018 $3,492
Q1 2018 $2,286
Q4 2017 $3,203
Q3 2017 $1,300
Q2 2017 $3,694
Q1 2017 $3,276
Q4 2016 $194
Q3 2016 $4,245
Q2 2016 $3,207
Q1 2016 $3,324
Q4 2015 $3,512
Q3 2015 $3,910
Q2 2015 $3,345
Q1 2015 $3,155
Q4 2014 $3,099
Q3 2014 $3,311
Q2 2014 $3,157
Q1 2014 $3,807
Q4 2013 $3,851
Q3 2013 $4,170
Q2 2013 $3,140
Q1 2013 $3,492
Q4 2012 $3,625
Q3 2012 $4,093
Q2 2012 $4,589
Q1 2012 $4,548
Q4 2011 $3,856
Q3 2011 $4,279
Q2 2011 $4,238
Q1 2011 $4,030
Q4 2010 $1,425
Q3 2010 $3,300
Q2 2010 $3,391
Q1 2010 $2,620
Q4 2009 $1,015
Q3 2009 $2,034
Q2 2009 $1,911
Q1 2009 $1,638
Q4 2008 $1,787
Q3 2008 $1,956
Q2 2008 $1,931
Q1 2008 $2,042
Q4 2007 $2,096
Q3 2007 $1,653
Q2 2007 $1,945
Q1 2007 $1,912
Q4 2006 $849
Q3 2006 $1,114
Q2 2006 $1,959
Q1 2006 $2,034
Q4 2005 $1,542
Q3 2005 $1,997
Q2 2005 $2,010
Q1 2005 $2,019
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $221.869B $42.294B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $367.316B 16.74
Pfizer (PFE) United States $249.127B 13.95
Novartis AG (NVS) Switzerland $215.800B 18.35
Eli Lilly (LLY) United States $132.844B 23.08
Novo Nordisk (NVO) Denmark $123.936B 20.05
AbbVie (ABBV) United States $117.653B 10.08
Sanofi (SNY) France $111.008B 13.70
AstraZeneca (AZN) United Kingdom $107.876B 12.31
GlaxoSmithKline (GSK) United Kingdom $102.325B 13.44
Bristol-Myers Squibb (BMY) United States $78.630B 12.10